Research programme: thalassemia therapy - ChiesiAlternative Names: S-DFO
Latest Information Update: 15 Feb 2007
At a glance
- Originator Chiesi
- Mechanism of Action Fetal haemoglobin stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Thalassaemia
Most Recent Events
- 15 Jan 2007 Chiesi remains committed to developing a compound for the treatment of beta-thalassemia
- 24 Feb 2004 This programme is still in active development
- 22 Aug 2000 Preclinical development for Thalassaemia in Italy (Unknown route)